Davies Scores Top Ranking in Global Competition Review 2020

For the 12th consecutive year, Global Competition Review has named Davies an “Elite” Canadian firm in its annual listing of the world’s top competition practices – the highest category awarded in the jurisdiction.

The guide commends our role in a “long list of global deals” over the past year, as well as our continued track record of success in competition litigation. A sampling of our recent notable work includes acting for Celgene Corp. in its proposed US$74-billion purchase by Bristol-Myers Squibb Co.; acting for Monsanto on its €57-billion sale to Bayer, Pfizer on its proposed deal with GlaxoSmithKline related to their consumer healthcare businesses; and the Liquor Control Board of Ontario in successfully defending a multi-billion dollar class action alleging a price-fixing conspiracy.

Compiled independently, the GCR 100 provides a qualitative analysis of the law firms doing the most important competition and antitrust work around the world.


Top Competition and Foreign Investment Review Trends and Issues for 2020

Jan. 21, 2020 - In our annual forecast of the year ahead for Canadian competition and foreign investment review law, we evaluate how developments in 2019 will influence these areas of the law in 2020. We discuss below the main issues and trends to watch for this year. Continued Focus on Enforcement in the...